Niagen Bioscience NAGE Income Statement (2010-2026)

NASDAQ NAGE
$2.19 -0.09 (-3.73%)
As of: Nov 10, 2026 · 10:13 AM EST
Reported Financials

Niagen Bioscience Quarterly Income Statement

Periods 62 quarters
Latest Sep 2026

Niagen Bioscience reported revenue of $27.19M and net income of -$1.17M for the quarter ended Sep 2026, down 20.0% year over year. This income statement covers 62 quarters of results from Oct 2010 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Oct2010 Jan2011 Apr2011 Jul2011 Oct2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Mar2014 Jun2014 Sep2014 Jan2015 Apr2015 Jul2015 Oct2015 Jan2016 Apr2016 Jul2016 Oct2016 Dec2016 Apr2017 Jul2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
17.76M17.26M16.73M17.06M21.00M22.56M20.32M19.50M21.20M22.15M22.74M25.58M29.13M30.48M31.12M33.99M33.84M31.47M29.79M27.19M
Cost of RevenueCost of Rev
6.89M6.73M6.69M6.86M8.98M9.04M7.97M7.53M8.26M8.70M9.05M9.34M10.93M11.15M10.89M12.06M12.14M11.50M10.47M10.09M
Gross Profit
10.87M10.53M10.04M10.21M12.02M13.52M12.36M11.97M12.94M13.46M13.69M16.24M18.20M19.33M20.23M21.93M21.70M19.98M19.31M17.11M
Operating items
Research & DevelopmentR&D
1.05M1.08M1.25M1.22M1.28M1.19M1.37M1.24M1.16M2.10M1.32M1.29M1.32M1.26M1.57M1.80M1.71M1.48M1.51M1.80M
Selling, General & AdministrativeSG&A
6.50M8.95M7.16M6.18M5.99M6.42M7.30M5.84M5.43M5.35M5.66M6.30M1.06M5.18M7.27M7.13M7.48M7.24M6.97M8.18M
Other Operating ExpensesOther Opex
8.64M8.24M8.02M5.87M6.19M7.87M6.01M6.04M6.52M6.74M6.97M7.04M8.72M8.12M8.21M8.77M8.43M9.68M10.13M8.71M
Operating ExpensesOpex
16.18M18.26M16.43M13.27M13.46M15.49M14.67M13.12M13.11M14.19M13.95M14.64M11.09M14.56M17.04M17.69M17.62M18.40M18.61M18.69M
Operating IncomeOp. Inc
-5.32M-7.73M-6.39M-3.07M-1.44M-1.97M-2.32M-1.15M-0.17M-0.73M-0.26M1.60M7.11M4.77M3.19M4.24M4.09M1.58M0.70M-1.59M
Non-operating items
Non Operating Interest Expenses
0.01M0.01M0.01M0.01M
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
4.80M0.00M
Interest & Investment IncomeInt & Inv Inc
Other Non Operating IncomeOther Non Op Inc.
Non Operating IncomeNon Op. Inc.
Net income details
EBIT
-5.32M-7.73M-6.39M-3.07M-1.44M-1.97M-2.32M-1.15M-0.17M-0.73M-0.26M1.60M7.11M4.77M3.19M4.24M4.09M1.58M0.70M-1.59M
EBT
-5.33M-7.74M-6.40M-3.07M-1.44M-1.97M-2.32M-1.15M-0.17M-0.49M-0.02M1.88M7.48M5.23M3.74M4.80M4.42M6.74M1.07M-1.17M
Tax ProvisionsTaxes
0.31M0.17M0.13M0.22M0.29M0.42M0.11M
Income After Tax
-5.33M-7.74M-6.40M-3.07M-1.44M-1.97M-2.32M-1.15M-0.17M-0.49M-0.02M1.88M7.18M5.06M3.61M4.58M4.13M6.32M0.96M-1.17M
Income from Continuing OperationsIncome (Continuing)
-5.33M-7.74M-6.40M-3.07M-1.44M-1.97M-2.32M-1.15M-0.17M-0.49M-0.02M1.88M7.18M5.06M3.61M4.58M4.13M6.32M0.96M-1.17M
Income from Discontinued OperationsIncome (Discontinued)
Consolidated Net IncomeConsol Net Inc.
-5.33M-7.74M-6.40M-3.07M-1.44M-1.97M-2.32M-1.15M-0.17M-0.49M-0.02M1.88M7.18M5.06M3.61M4.58M4.13M6.32M0.96M-1.17M
Income towards Parent CompanyParent Net Inc
-5.33M-7.74M-6.40M-0.99M-1.42M-1.90M-2.19M-0.96M0.11M-0.49M-0.02M1.88M7.18M5.06M3.61M4.58M4.08M6.32M0.96M-1.17M
Net Income towards Common StockholdersNet Income
-5.33M-7.74M-6.40M-0.99M-1.42M-1.90M-2.19M-0.96M0.11M-0.49M-0.02M1.88M7.18M5.06M3.61M4.58M4.08M6.32M0.96M-1.17M
Additional items
EPS (Basic)
-0.08-0.11-0.09-0.01-0.02-0.03-0.03-0.010.00-0.010.000.020.090.070.050.060.050.080.01-0.01
EPS (Diluted)
-0.08-0.11-0.09-0.01-0.02-0.03-0.03-0.010.00-0.010.000.020.090.060.040.050.050.070.01-0.01
Shares Outstanding
67.19M68.31M68.34M68.35M69.73M74.80M74.97M75.05M74.99M75.23M75.56M75.97M75.93M77.81M79.25M79.78M79.18M79.92M79.32M79.15M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
67.19M68.31M68.34M68.35M69.73M74.80M74.97M75.05M74.99M75.23M75.56M77.77M78.13M83.23M86.24M86.62M85.44M84.57M82.50M79.15M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
68.13M68.15M68.16M68.17M74.57M74.67M74.86M74.91M74.98M75.15M75.47M76.03M77.33M78.43M79.59M79.64M79.71M79.46M78.91M79.03M
EBITDA
-5.05M-7.48M-6.13M-2.79M-1.18M-1.70M-2.05M-0.88M0.05M-0.52M-0.05M1.80M7.30M4.97M3.38M4.43M4.29M1.87M0.99M-1.30M
Interest ExpensesInt Expense
0.01M0.01M0.01M0.01M
Tax Rate
4.08%3.21%3.43%4.63%6.60%6.19%9.92%

Niagen Bioscience Income Statement API

Pull Niagen Bioscience's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=NAGE&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY